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Introduction {#sec1}
============

Proximal spinal muscular atrophy (SMA) is the most common form of fatal motoneuron diseases in childhood. SMA is caused by loss or compound heterozygous mutations within the survival motoneuron gene (*SMN1*) that results in deficiency of the SMN protein ([@bib27]). Although genetically issued therapeutic strategies ([@bib16], [@bib41], [@bib43], [@bib44], [@bib61]) are under consideration, it is unknown how SMN deficiency dysregulates cellular mechanisms in motoneurons. A defective Ca^2+^ homeostasis was discussed in glial and neuronal cells in SMA animal models ([@bib2], [@bib3], [@bib19], [@bib33], [@bib34], [@bib46], [@bib49], [@bib54]). Embryonic motoneurons in primary cultures from SMA mouse models show reduced N-type (Ca~v~2.2) voltage-gated calcium channel (VGCC) cumuli in their protrusions ([@bib19]) that corresponds to altered axonal extension on a synapse-specific laminin isoform (laminin-221) and on a Schwann cell-specific isoform (laminin-111) ([@bib19], [@bib48]). At the neuromuscular junction (NMJ), motor nerve terminals from SMA mice also display a reduction in P/Q-type (Ca~v~2.1) VGCCs ([@bib58]), which correlates with the neurotransmission deficit ([@bib24], [@bib49]).

To test whether the re-balancing of the dysregulated Ca^2+^ homeostasis compensates for motoneuron defects, we used the small molecule Roscovitine. R- and S-Roscovitine are stereoisomers originally described as equally effective inhibitors of cyclin-dependent kinases (Cdks), in particular Cdk-5 ([@bib35], [@bib36]). In addition, R-Roscovitine slows the deactivation (closing) kinetics of Ca~v~2.1 and Ca~v~2.2 channels, which prolongs the open state of the channels and increases calcium influx ([@bib64]). In contrast, S-Roscovitine has no effect on the deactivation of the channels and can even inhibit Ca^2+^ influx ([@bib5]). *In vitro*, R-Roscovitine increases Ca^2+^ influx and transmitter release at presynaptic terminals of cultured hippocampal neurons independent of its Cdk-5 inhibitory effect ([@bib6], [@bib64]). In frog neuromuscular preparations, R-Roscovitine, but not S-Roscovitine, increases the number of acetylcholine quanta released during electrical stimulation ([@bib8]).

Our data indicate that R-Roscovitine increases SMA mouse survival and beneficially supports motoneuron differentiation, as well as synapse maintenance in the spinal cord, and counteracts morphological defects of the NMJ in an SMA mouse model (*Smn*^*−/−*^*;SMN2;SMNΔ7*). Finally, acute R-Roscovitine application induces Ca^2+^ transients *in vitro* and increases quantal content (QC) *ex vivo*. We conclude that these effects are primarily mediated through the capability of R-Roscovitine to enhance Ca^2+^ currents.

Results {#sec2}
=======

Increased Mean Lifespan of SMA Mouse Models upon Systemic R-Roscovitine Treatment {#sec2.1}
---------------------------------------------------------------------------------

We used different severe SMNΔ7 mouse models (groups 1 and 2, [Figure 1](#fig1){ref-type="fig"}A) to investigate the effect of R-Roscovitine on their survival. To discern whether the impact of R-Roscovitine is due to its inhibitory effect on Cdk-5, we used S-Roscovitine as a control, which inhibits Cdk-5 as well as R-Roscovitine but does not increase Ca^2+^ influx. Pregnant heterozygous SMA mice were daily injected with R- or S-Roscovitine (2 mg/kg; see also [Supplemental Information](#mmc1){ref-type="supplementary-material"}, [Transparent Methods](#mmc1){ref-type="supplementary-material"}). In group 1, the mean survival of the homozygous SMA mice (*Smn*^*−/−*^*;SMN2tg/x;SMNΔ7tg/x*) treated with R-Roscovitine significantly increased (13.4 ± 6.2 days) when compared with untreated SMA mice (4.9 ± 2.0 days) ([Figures 1](#fig1){ref-type="fig"}B and 1C). Additional postnatal application of R-Roscovitine did not prolong survival of SMA mice (13.9 ± 5.5 days) ([Figures 1](#fig1){ref-type="fig"}B and 1C). To verify whether a consistent double transgenic (*SMN2tgtg;SMNΔ7tgtg*) background increases the mean survival after R-Roscovitine application, pregnant *Smn*^*+/-*^*;SMN2tgtg;SMNΔ7tgtg* mice were injected. The *SMN2tgtg;SMNΔ7tgtg* background (group 2) increased the mean survival rate up to approximately 14 days (14.0 ± 1.1 days) ([Figures 1](#fig1){ref-type="fig"}B blue curve; [1](#fig1){ref-type="fig"}C blue bar) comparable to previous reports ([@bib26]). R-Roscovitine application again elevated the mean survival significantly up to 19 days (18.9 ± 1.7 days) ([Figure 1](#fig1){ref-type="fig"}B, pink curve; [Figure 1](#fig1){ref-type="fig"}C pink bar). However, the maximum value of 23 days upon R-Roscovitine application to group 1 mice ([Figure 1](#fig1){ref-type="fig"}B, green curve) was not exceeded by the double transgenic *SMN2/Δ7* background (22 days) ([Figure 1](#fig1){ref-type="fig"}B, pink curve). No significant weight gain (until P9), but a non-significant delayed weight loss up to P12, had been observed following prenatal R-Roscovitine application in SMA mice from group 2 ([Figure S1](#mmc1){ref-type="supplementary-material"}A). However, a slight but non-significant effect on the righting reflex between P3 and P6 was detectable ([Figure S1](#mmc1){ref-type="supplementary-material"}B).Figure 1Prolonged Lifespan of SMA Mice under Systemic R-Roscovitine Treatment(A) Genotype of Smn-deficient mice used in the study.(B and C) (B) Survival curve and (C) mean survival rate of SMA mice in group 1: untreated (black), prenatally treated with R- or S-Roscovitine (green and gray, respectively), and pre- and postnatally treated with R-Roscovitine (purple); and in group 2: untreated (blue) and treated with R-Roscovitine (pink) (\*\*p \< 0.01; \*\*\*p \< 0.001, ANOVA and U Mann-Whitney).(D and E) (D) Survival curve and (E) mean survival rate of group 1 postnatally treated SMA mice with PBS (yellow), DMSO (orange) and R-Roscovitine (red) (\*\*\*p \< 0.001, ANOVA).(F--I) Representative images for each example from postnatal application depicted at days (F) 2, (G) 5, (H) 10, and (I) 12.Bars represent mean ± SD; n defines the number of mice; n.s., no significance.

Prenatal injection of S-Roscovitine had no beneficial effect on the survival of SMA mice (5.7 ± 2.3 days) ([Figure 1](#fig1){ref-type="fig"}B gray curve, [Figure 1](#fig1){ref-type="fig"}C gray bar). To test if R-Roscovitine compensates for reduced survival of SMA mice when first clinical symptoms already appeared, Smn-deficient mouse pups from group 1 received a postnatal injection at P2 with R-Roscovitine (1.5 mg/kg) reaching a blood serum concentration of about 50--100 μM (see also [Supplemental Information](#mmc1){ref-type="supplementary-material"}, [Transparent Methods](#mmc1){ref-type="supplementary-material"}). Application of R-Roscovitine significantly extended the mean lifespan to 9.3 ± 2.7 days, compared with Smn-deficient pups treated with PBS (3.8 ± 1.8 days) or DMSO (5.8 ± 1.5 days) ([Figures 1](#fig1){ref-type="fig"}D and 1E). Representative examples of postnatal treated and non-treated mice from group 1 are depicted in [Figures 1](#fig1){ref-type="fig"}F--1I.

Prenatal Treatment with R-Roscovitine Decreases Loss of Spinal Motoneurons, Increases the Number of Excitatory Somatodendritic Inputs on Motoneurons, and Beneficially Affects Ca~v~2.1 Channel Cluster Formation in SMNΔ7 Mice {#sec2.2}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

To analyze the cellular effects of R-Roscovitine on motoneuron loss, the number of excitatory somatodendritic inputs, the area of NMJs, Ca~v~2.1 cluster formation, as well as muscle fiber caliber were compared between control and SMA mice (group 2). To check whether prenatal treatment with R-Roscovitine changed the number of spinal motoneurons in SMA mice, acetyltransferase (ChAT)-positive cells were labeled and their number estimated at the upper lumbar regions (L1-L2), which are particularly vulnerable in SMA ([@bib37]). [Figure 2](#fig2){ref-type="fig"}A shows an example of the distribution of labeled neurons and the mean number of motoneurons estimated in non-treated and prenatally treated control and SMNΔ7 mice. In the absence of the drug, mutants showed a significant reduction by 40% with respect to their control littermates. However, in treated mutants the number of motoneurons was not significantly different from their controls ([Figure 2](#fig2){ref-type="fig"}A). We next checked whether the number of excitatory somatodendritic inputs on motoneurons was modified by the drug treatment. We found no significant differences in the density or the number of VGlut2-positive inputs per μm^2^ at the soma between mutants and their littermate controls in the group treated with R-Roscovitine, contrarily to that found in the non-treated group ([Figure 2](#fig2){ref-type="fig"}B). To test whether R-Roscovitine had an effect on the pre- and postsynaptic sides of the NMJ, we quantified the postsynaptic area ([Figure 2](#fig2){ref-type="fig"}C) and determined the Ca~v~2.1 cluster formation in the presynaptic compartment ([Figure 2](#fig2){ref-type="fig"}D) of the *transversus abdominis* (TVA), one of the most affected muscles in the disease model ([@bib58], [@bib60]). In non-treated mice the endplate surface area was reduced significantly in mutants when compared with littermate controls, whereas no differences were found between the two genotypes when mice were treated with R-Roscovitine ([Figure 2](#fig2){ref-type="fig"}C). Additional effects were observed after antibody stainings against the P/Q-type VGCC (Ca~v~2.1). R-Roscovitine beneficially affected Ca~v~2.1 cluster formations in mutant NMJs indicated by the ratio between P/Q area and BTX area ([Figure 2](#fig2){ref-type="fig"}D upper and lower panels). Finally, we investigated muscle fiber area and perimeter of the TVA. Contrarily, no improvement in myofiber surface area or perimeter was found following R-Roscovitine treatment ([Figure 2](#fig2){ref-type="fig"}E). To figure out whether muscle innervation is influenced by R-Roscovitine treatment we used the flexor digitorum brevis (FDB3) muscle, which has been described to be one of the most denervated in Smn-deficient mice ([@bib30]). Surprisingly, we found a low number of unoccupied endplates in both genotypes, and no significant changes in R-Roscovitine-treated mice compared with untreated mice ([Figure S1](#mmc1){ref-type="supplementary-material"}C).Figure 2Prenatal Treatment with R-Roscovitine Reduces Spinal Motoneuron Loss, Ameliorates the Decrease of Excitatory Synaptic Inputs, and Increases Endplate Surface Area and Ca~v~2.1 Accumulation Area, but Not Muscle Fiber Size In SMNΔ7 Mice(A) Quantification (right panel) of ChAT-positive L1-L2 spinal neurons (left panel) in untreated (left bars) and R-Roscovitine-treated (right bars) mice (\*\*p \< 0.01, ANOVA).(B) Representative examples of excitatory synaptic inputs onto L1-L2 motoneurons in control and SMA mice; z stack projections of confocal images, 2 μm (5 optical sections) for the indicated genotypes and conditions (left panel). Densities of VGlut2-positive inputs per soma (right panel) (\*\*p \< 0.01, ANOVA) (scale bar, 10 μm).(C) Representative images of endplates labeled with bungarotoxin (BTX) conjugated to rhodamine in control and SMA TVA muscles (left panel). Mean values of BTX surface area in all four conditions (right panel) (\*\*p \< 0.01; \*\*\*p \< 0.001; ANOVA) (scale bar, 10 μm).(D) Ca~v~2.1 channel distribution in control and Smn-deficient neuromuscular junctions (upper panel) indicated by the ratio of the P/Q-BTX area (lower panel) (\*p \< 0.05; \*\*\*p \< 0.001, ANOVA) (scale bar, 10 μm).(E) The skeletal muscle membrane was evidenced in transversal slices (20 μm) stained against lectins with rhodamine-labeled WGA; representative images per condition (left panel); mean values for area and perimeter (right panel) (\*\*p \< 0.01, ANOVA) (scale bar, 50 μm).Bars represent mean ± SEM. The second number inside bars defines the number of mice; the first number is the number of motoneurons in (A and B), the number of neuromuscular junctions in (C and D), and the number of myofibers in (E); n.s., no significance. See also [Figures S1](#mmc1){ref-type="supplementary-material"}A--S1C.

R-Roscovitine Increases Calcium Signaling of Primary Cultured SMA Motoneurons {#sec2.3}
-----------------------------------------------------------------------------

The *in vivo* results raised the possibility that the delay in motoneuron loss and the larger P/Q-VGCC surface area at motor nerve terminals were, in part, due to the capability of R-Roscovitine to slow down the deactivation kinetics of Ca~v~2.2/2.1 channels and, therefore, to increase cytosolic Ca^2+^ levels. Thus, we analyzed acute and long-term effects of the drug on axons and axonal nerve endings of isolated embryonic motoneurons from Smn-deficient mouse embryos. As SMA motoneurons cultured on the β2 chain-containing laminin isoform (laminin-221) display a reduction in spontaneous spike-like Ca^2+^ transients and reduced Ca~v~2.2 cluster formations at the growth cone ([@bib19]), we examined whether R-Roscovitine modulates Ca^2+^ transients in motoneurons. We started our approach with an acute application of 5 μM R- as well as S-Roscovitine, given that primary cultured motoneurons are very vulnerable and that in cultured hippocampal neurons acute application of 10 μM R-Roscovitine effectively increases synaptic potentials ([@bib59]). In control motoneurons at 5 days *in vitro* (DIV 5) the acute application of 5 μM R-Roscovitine, but not S-Roscovitine, led to an immediate and continuous induction of Ca^2+^ transients both in the soma and growth cone ([Figure 3](#fig3){ref-type="fig"}A), whereas the acute application of 0.5 μM R-Roscovitine had no effect ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Next, we wanted to know whether the Ca^2+^ transients evoked by acute R-Roscovitine application might also cause a continuous/general increase of spontaneous Ca^2+^ transients in Smn-deficient motoneurons during chronic exposure to the drug over 5 days. Thus, we investigated the long-term effects of both drugs on motoneurons *in vitro*. As R- or S-Roscovitine at concentrations higher than 1 μM diminished survival in dissociated motoneurons over 5 days in culture ([Figure S3](#mmc1){ref-type="supplementary-material"}A), all further long-term *in vitro* experiments were performed with an end concentration of 0.5 μM R- or S-Roscovitine. Chronic R-Roscovitine treatment for 5 days compensated the reduced frequency of spontaneous spike-like Ca^2+^ transients at Smn-deficient distal axons ([Figure 3](#fig3){ref-type="fig"}B, right and middle panel). Single values per neuron are depicted in [Figure 3](#fig3){ref-type="fig"}B, left panel. This effect was blocked when 0.3 μM ω-conotoxin (ω-CTX-MVIIC), a Ca~v~2.2/2.1 inhibitor, was present during the cell culture period ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Nevertheless, permanent application of 0.5 μM S-Roscovitine for 5 days to Smn-deficient motoneurons resulted in a moderate, but not significant, increase in the frequency of spontaneous spike-like transients ([Figure 3](#fig3){ref-type="fig"}B, left, right, and middle panel). To rule out VGCC-affecting attitudes of Cdk-5, motoneurons from *Cdk-5* knockout mouse embryos were cultured with and without 0.5 μM R-Roscovitine over 5 days and processed for calcium imaging studies at DIV 5. Cdk-5 deficiency had no effect on spontaneous Ca^2+^ transients ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Taking together, these observations are compatible with the calcium channel-modulating properties of R-Roscovitine through its ability to slow the closing time of Ca~v~2.1 and Ca~v~2.2 channels. Furthermore, the potential inhibition of Cdk-5 by 0.5 μM R-Roscovitine did not impact its capability to rescue altered excitability in axon terminals of primary cultured Smn-deficient motoneurons.Figure 3Application of R-Roscovitine Leads to Enhanced Spontaneous Ca^2+^ Transients in *Smn*^*−/−*^*;SMN2* Motoneurons(A) Representative responses of control motoneurons to 40-s application of 5 μM S-Roscovitine followed by R-Roscovitine in the soma and the growth cone.(B) Permanent application of R- or S-Roscovitine over 5 days in culture. The left panel shows the frequency of Ca^2+^ transients per neuron at the growth cone of control and SMA motoneurons untreated and under permanent R- or S-Roscovitine exposure (\*\*p \< 0.01, ANOVA). The red line defines the mean values. The middle panel depicts the associated bar diagram (mean ± SEM) (\*\*p \< 0.01, ANOVA). The right panels show spontaneous Ca^2+^ spikes indicated by red dots in their corresponding growth cones. N defines number of cells, n indicates number of experiments (N/n); n.s., no significance.See also [Figures S2](#mmc1){ref-type="supplementary-material"}A--S2C and [S3](#mmc1){ref-type="supplementary-material"}A.

Chronic Application of R-Roscovitine Improves Differentiation of SMA Motoneurons in Culture {#sec2.4}
-------------------------------------------------------------------------------------------

To figure out whether the increase of spontaneous Ca^2+^ transients might cause long-term support of cellular differentiation of Smn-deficient motoneurons, we performed a morphological analysis. Given that Smn-deficient motoneurons in culture display smaller growth cone sizes ([@bib19]), we checked the ability of R-Roscovitine (0.01--0.5 μM, for 5 days) to compensate it. We found that the effect of R-Roscovitine acts in a dose-dependent manner, with 0.5 μM being required for full compensation ([Figures 4](#fig4){ref-type="fig"}A--4D). Strikingly, mean signal intensity of the calcium channel "clusters" measured by immunofluorescence was also restored to control level upon permanent R-Roscovitine treatment over 5 days ([Figures 4](#fig4){ref-type="fig"}A--4C and 4E). These effects of R-Roscovitine were independent of Smn protein levels as the total transcript and protein amount was unaffected ([Figures S3](#mmc1){ref-type="supplementary-material"}B and S3C).Figure 4Permanent Exposure to R-Roscovitine Supports Cellular Differentiation of *Smn*^*−/−*^*;SMN2* Motoneurons(A--C) Representative immunofluorescent images of growth cones on day 5 stained with antibodies against Ca~v~2.2 channels (green) and phalloidin (magenta) of control (A) and SMA motoneurons, untreated (B) or permanently treated (C) with 0.5 μM R-Roscovitine (R-Rosc.) (scale bar, 5 μm).(D) The growth cone area sizes were quantified on different concentrations (0, 0.01, 0.05, 0.1, 0.5 μM) of R-Roscovitine in SMA motoneurons (\*\*p \< 0.01; \*\*\*p \< 0.001; ANOVA).(E) Quantification of signal intensities representing Ca~v~2.2 channel cluster formations at growth cones (\*\*\*p \< 0.001; ANOVA).(F) Axon lengths of R-Roscovitine (0.5 μM) and CTX-treated (ω-CTX-MVIIC, 0.3 μM) and untreated Smn-deficient and control motoneurons cultured on laminin-221/211 or on laminin-111 on day 7 (\*\*p \< 0.01; \*\*\*p \< 0.001; ANOVA).(G) Axon lengths of S-Roscovitine (S-Rosc.)-treated Smn-deficient and control motoneurons on laminin-221/211 or laminin-111 on day 7 (\*p \< 0.05; \*\*\*p \< 0.001, ANOVA).(H) Comparison of axon lengths between GV-58 versus S- or R-Roscovitine-treated SMA motoneurons on laminin-221/211 after 7 days in culture (\*p \< 0.05, \*\*\*p \< 0.001; ANOVA).Bars represent mean ± SEM. Numbers inside bars define number of cells and number of experiments, respectively; n.s., no significance. See also [Figures S3](#mmc1){ref-type="supplementary-material"}B, S3C, and [S4](#mmc1){ref-type="supplementary-material"}A--S4C.

In addition, reduced spontaneous Ca^2+^ transients in Smn-deficient motoneurons and ω-CTX-MVIIC-treated control cells are associated with altered axon elongation on different laminin isoforms ([@bib19]). In the presence of 0.5 μM R-Roscovitine, however, axon lengths of Smn-deficient motoneurons, both on Schwann cell-specific laminin (laminin-111) and in the synapse-specific laminin (laminin-221/211), reached control values on day 7 (DIV 7) ([Figure 4](#fig4){ref-type="fig"}F). The presence of 0.3 μM ω-CTX-MVIIC over 7 days increased the length of control axons to mutant level and prevented the R-Roscovitine-induced rescue in mutant cells on both laminin isoforms ([Figure 4](#fig4){ref-type="fig"}F). S-Roscovitine did not affect axon elongation on laminin-111 or laminin-221/211 significantly ([Figure 4](#fig4){ref-type="fig"}G), which supports the notion that R-Roscovitine modulates motoneuron differentiation via Ca~v~2.2 channels. To further test this hypothesis, we compared axon lengths of Smn-deficient motoneurons following treatment with R- and S-Roscovitine and GV-58. GV-58, an N- and P/Q-type VGCC agonist with a 20-fold lower cyclin-dependent kinase antagonist activity ([@bib29]), has already been investigated in a mouse model for Lambert-Eaton syndrome ([@bib56]). GV-58 application for 7 days adjusted axon lengths of Smn-deficient motoneurons to wild-type level on laminin-221/211, like R-Roscovitine, but not S-Roscovitine ([Figure 4](#fig4){ref-type="fig"}H). Finally, we also checked whether 0.5 μM R-Roscovitine has any effect on the Cdk-5 substrate Pak1 or the p35/25 activators and found no changes in western blot measurements ([Figures S4](#mmc1){ref-type="supplementary-material"}A--S4C).

Gene Expression of Ca~v~2.2/2.1 Channels Is Not Up- or Downregulated in Cultured SMA Motoneurons following R-Roscovitine Treatment {#sec2.5}
----------------------------------------------------------------------------------------------------------------------------------

Previous reports have shown altered gene expression under Smn deficiency ([@bib9], [@bib14], [@bib18], [@bib50]). This poses the question of whether the beneficial effect(s) on VGCCs via R-Roscovitine is(are) due to upregulated gene expression of Ca~v~2.2/2.1 channels. To explore this, we collected the RNA for high-throughput sequencing (RNA sequencing \[RNA-Seq\]) from primary Smn-deficient and control motoneurons cultured on laminin-111 and treated with and without R-Roscovitine, respectively ([Figure 5](#fig5){ref-type="fig"}, [Tables S1--S7](#mmc2){ref-type="supplementary-material"}). Differential expression analysis revealed 2,404 transcripts that were significantly (p \< 0.05) altered in untreated *Smn*^*−/−*^*;SMN2* compared with untreated *Smn*^*+/+*^*;SMN2* motoneurons (1,011 up- and 1,393 downregulated transcripts) ([Figure 5](#fig5){ref-type="fig"}A and [Table S1](#mmc2){ref-type="supplementary-material"}). The transcript level of *SMN2* is not affected by R-Roscovitine ([Figure S3](#mmc1){ref-type="supplementary-material"}B). Addition of R-Roscovitine induced significant alterations of 612 transcripts (464 up- and 148 downregulated transcripts) in *Smn*^*−/−*^*;SMN2* motoneurons and of 898 transcripts (582 up- and 316 downregulated transcripts) in *Smn*^*+/+*^*;SMN2* motoneurons ([Figure 5](#fig5){ref-type="fig"}A and [Tables S2](#mmc2){ref-type="supplementary-material"} and [S3](#mmc2){ref-type="supplementary-material"}). Strikingly, of the 612 transcripts whose levels were changed by R-Roscovitine in Smn-deficient motoneurons 357 were also significantly altered between *Smn*^*+/+*^*;SMN2* and *Smn*^*−/−*^*;SMN2* motoneurons ([Figure 5](#fig5){ref-type="fig"}B and [Table S4](#mmc2){ref-type="supplementary-material"}). The magnitude of change for these 357 transcripts was strongly negatively correlated with a Pearson correlation coefficient of −0.87 ([Figure 5](#fig5){ref-type="fig"}C). As a result, we detected 305 transcripts that were downregulated in *Smn*^*−/−*^*;SMN2* compared with *Smn*^*+/+*^*;SMN2* motoneurons and upregulated by R-Roscovitine treatment in *Smn*^*−/−*^*;SMN2* motoneurons ([Figures 5](#fig5){ref-type="fig"}C and [Table S5](#mmc2){ref-type="supplementary-material"}). Subunits of Ca~v~2.2, as well as Ca~v~2.1, were not among this set of transcripts ([Table S5](#mmc2){ref-type="supplementary-material"}). Gene Ontology (GO) term analysis of these 305 transcripts revealed enrichment of transcripts encoding proteins with functions in neuronal differentiation, neurotransmitter transport, and location at the synapse ([Figure 5](#fig5){ref-type="fig"}D and [Table S6](#mmc2){ref-type="supplementary-material"}). We also detected 40 transcripts that were upregulated in *Smn*^*−/−*^*;SMN2* compared with *Smn*^*+/+*^*;SMN2* motoneurons and downregulated by R-Roscovitine treatment in *Smn*^*−/−*^*;SMN2* motoneurons ([Figure 5](#fig5){ref-type="fig"}C and [Table S7](#mmc2){ref-type="supplementary-material"}). Taken together, R-Roscovitine treatment partially rescued the transcriptome perturbations induced by reduced SMN expression, although no effect on the expression of Ca~v~2.2, as well as Ca~v~2.1 channels was detectable.Figure 5R-Roscovitine Affects the RNA Profile of Smn-Deficient Motoneurons(A) Volcano plots showing the significance of change (-log~10~(p value)) and the magnitude of change (log~2~(fold change), log~2~FC) for each transcript for the indicated differential expression analyses. Significantly altered transcripts with p \< 0.05 are marked in red. For easier visualization data points for transcripts with log~2~FC \< −10 or \>10 (all of which were not significantly altered) were omitted.(B) Overlap of transcripts significantly changed (p \< 0.05) in the indicated differential expression analyses.(C) Scatterplot showing the magnitude of change (log~2~(fold change), log~2~FC) of the transcripts indicated in (B) that are significantly altered in untreated *Smn*^*−/−*^*;SMN2* compared with untreated *Smn*^*+/+*^*;SMN2* motoneurons and also significantly altered in R-Roscovitine-treated *Smn*^*−/−*^*;SMN2* compared with untreated *Smn*^*−/−*^*;SMN2* motoneurons. Note that in the scatterplot only transcripts that were detectable under all conditions are shown (351 of the 357 transcripts indicated in (B)).(D) Gene ontology (GO) term analysis of the 305 transcripts indicated by the red box in (C).See also [Figure S3](#mmc1){ref-type="supplementary-material"}B and [Tables S1--S7](#mmc2){ref-type="supplementary-material"}.

Acute Exposition to R-Roscovitine Increases Neurotransmitter Release in Motor Nerve Terminals from SMA and Control Mice {#sec2.6}
-----------------------------------------------------------------------------------------------------------------------

Our data suggest that the cell-autonomous and excitability-associated defects of cellular differentiation in primary Smn-deficient motoneurons ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}) and of the neuromuscular system in SMA mice ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}) can be improved by the modulatory effect of R-Roscovitine on VGCCs. Thus, we decided to transfer our studies on *ex vivo* neuromuscular preparations from SMNΔ7 (group 2) mice. We investigated if R-Roscovitine was able to increase neurotransmitter release at the NMJ by performing intracellular recordings of postsynaptic potentials in the presence and absence of the drug. The experiments were performed in the TVA muscle of Smn-deficient and littermate control mice at P9-P11, a stage at which neurotransmission is highly affected ([@bib24], [@bib49], [@bib58], [@bib60]). Following the calculated concentrations achieved by subcutaneous application of R-Roscovitine in pregnant mice and postnatal mouse pups (see [Supplemental Information](#mmc1){ref-type="supplementary-material"}, [Transparent Methods](#mmc1){ref-type="supplementary-material"}), in each experiment, a number of fibers were first recorded in the absence of the drug (control solution) and then in the presence of R-Roscovitine (10, 50, 100 μM) after 20--30 min of incubation. 100 μM R-Roscovitine did not modify the amplitude of spontaneous miniature endplate potentials (mEPPs), neither in control nor in SMA terminals ([Figure 6](#fig6){ref-type="fig"}A), but significantly increased the mEPP frequency in both genotypes ([Figure 6](#fig6){ref-type="fig"}B). The EPP amplitudes greatly increased in control (∼280%) and SMA (∼295%) terminals in the presence of 100 μM R-Roscovitine ([Figures 6](#fig6){ref-type="fig"}C and 6E). QC, the ratio between mean EPP and mean mEPP amplitudes, was similarly elevated in the presence of the drug both in control and SMA mice ([Figures 6](#fig6){ref-type="fig"}D and 6F). In contrast, 10 μM R-Roscovitine had no effect on mEPP and EPP amplitudes or QC in control or SMA nerve terminals ([Figures S2](#mmc1){ref-type="supplementary-material"}D--S2F). Although 50 μM showed no significant effect, it tended to increase EPP amplitude and QC. This is in line with the effective dose to increase neurotransmitter release at the adult frog NMJ ([@bib8]). S-Roscovitine and olomoucine, another structurally related cyclin-dependent kinase inhibitors, were not able to increase neurotransmitter release, similar to what has been described before at the frog NMJ ([@bib8]). In fact, S-Roscovitine had a significant inhibitory effect on neurotransmission, which was partially reversible ([Figures 6](#fig6){ref-type="fig"}G and 6H), whereas olomoucine (100 μM) had no effect at all (QC: 6.02 ± 0.36 in the absence, and 5.72 ± 0.21 in the presence of the drug, six fibers in each condition).Figure 6R-Roscovitine Increases Spontaneous and Evoked Neurotransmitter Release at Control and SMNΔ7 Mouse Motor Nerve Terminals(A and B) (A) Amplitude and (B) frequency of spontaneous events (mEPPs) in both genotypes with and without R-Roscovitine (100 μM) (\*\*\*p \< 0.001, ANOVA).(C and D) Average EPP size (C) and quantum content (D) during 100 stimuli at 0.5 Hz in control and in SMA terminals with and without R-Roscovitine.(E and F) R-Roscovitine increases (E) mean EPP amplitude and (F) quantal content in both genotypes at low frequency of stimulation (0.5 Hz) (\*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001; ANOVA).(G) Representative EPP traces in control fibers before and after application of S-Roscovitine at the indicated concentrations.(H) Quantal content declines with S-Roscovitine concentrations higher than 10 μM (\*\*\*p \< 0.001, ANOVA). Bars represent mean ± SEM. N = number of muscle fibers, n = number of mice; n.s., no significance.See also [Figures S2](#mmc1){ref-type="supplementary-material"}D--S2F.

Acute Application of R-Roscovitine Increases the Probability of Neurotransmitter Release and Unmasks Silenced Terminals in SMA and Control Nerve Terminals {#sec2.7}
----------------------------------------------------------------------------------------------------------------------------------------------------------

To explore whether R-Roscovitine changes the probability of vesicle release, we measured the synaptic responses to two consecutive stimuli (pair pulse protocol, interstimulus interval 50 ms). In the absence of R-Roscovitine, the mean amplitude of the second EPP was larger than that of the first, indicating an increase in release probability between stimuli (short-term facilitation) in control and SMA terminals ([Figure 7](#fig7){ref-type="fig"}A, upper traces). In the presence of 100 μM R-Roscovitine, the synaptic facilitation significantly disappeared in both control and SMA mouse ([Figures 7](#fig7){ref-type="fig"}A lower panels, and 7B), suggesting a general increase in release probability.Figure 7R-Roscovitine Reduces Facilitation and Increases the Number of Active Motor Nerve Terminals in Control and SMNΔ7 Mice(A) Representative EPP traces from control and mutant muscle fibers before and after the application of 100 μM R-Roscovitine.(B) Quantification of paired-pulse ratio of response amplitudes in control and mutant muscle fibers with and without R-Roscovitine (\*p \< 0.05, ANOVA).(C) Representation of single (left) and double (right) EPPs in a control mouse. The arrows indicate the peak of each EPP.(D) Number of active terminals in the same control fiber before and after application of R-Roscovitine.(E) Proportion of recorded fibers with double EPPs with respect to the total number of fibers recorded, in control and mutant mice (\*\*p \< 0.01, ANOVA). Bars represent mean ± SEM. N = muscle fibers, n = number of mice (N/n); n.s., no significance.

Remarkably, the acute application of R-Roscovitine also significantly increased the number of muscle fibers that responded with double EPPs to a single nerve stimulus ([Figures 7](#fig7){ref-type="fig"}C and 7D). Double EPPs are a typical sign of multi-innervation, and the different timings of the peaks ([Figure 7](#fig7){ref-type="fig"}C) result from the distinct conduction velocities of each active axon terminal. Double EPPs are often recorded perinatally but become less frequent by two weeks of age as most muscle fibers become mono-innervated ([@bib51]). At P9-11, only a small percentage of the entire recorded fibers in the control solution presented double EPPs ([Figure 7](#fig7){ref-type="fig"}E, control ∼7%; mutant: ∼22%). By R-Roscovitine exposure, the fraction of recorded fibers with double EPPs increased in control and SMA mutants ([Figure 7](#fig7){ref-type="fig"}E, control: ∼ 48%; mutant: ∼67%).

R-Roscovitine Effect on Neurotransmitter Release Requires the Activation of P/Q-type Voltage-Gated Calcium Channels {#sec2.8}
-------------------------------------------------------------------------------------------------------------------

We next explored whether the R-Roscovitine effect on the NMJ required the activation of P/Q-type channels (Ca~v~2.1), the main VGCC at the age at which the recordings were made ([@bib47], [@bib52]). For this purpose, we used 200 nM ω-Agatoxin IVA (ω-Aga.) as a specific blocker of P/Q-type channels ([@bib47]) and found that the mean amplitude of EPPs was reduced by ∼ 99.2% ([Figure 8](#fig8){ref-type="fig"}A, left bar graph) and the QC by ∼ 99.1% ([Figure 8](#fig8){ref-type="fig"}A, right bar graph). Adding 100 μM R-Roscovitine to terminals with ω- Agatoxin IVA still being present did not increase the EPP amplitude or the QC ([Figure 8](#fig8){ref-type="fig"}A). Accordingly, in control mouse terminals where exposition to R-Roscovitine resulted in ∼84% mean increase in neurotransmitter release, subsequent application of ω- Agatoxin IVA completely blocked the evoked response ([Figure 8](#fig8){ref-type="fig"}B). In Smn-deficient mice, similar effects occurred; ω- Agatoxin IVA completely blocked neurotransmitter release after R-Roscovitine had increased EPP amplitude and QC ([Figure 8](#fig8){ref-type="fig"}B). These results indicate that R-Roscovitine was not able to affect motor terminal release when P/Q-type VGCCs were blocked with ω-Agatoxin IVA, suggesting that R-Roscovitine does not increase release through the activation of a different calcium source.Figure 8R-Roscovitine Effect on Evoked Neurotransmitter Release Requires the Activation of P/Q-type Calcium Channels in Control and SMNΔ7 Mice(A) Representative EPP traces recorded in a control fiber in physiological solution (untreated), in the presence of ω-Agatoxin IVA (ω-Aga.), and with R-Roscovitine (R-Rosc.) (100 μM) plus ω-Agatoxin IVA (ω-Aga.) (upper panel). ω-Agatoxin IVA reduced the mean amplitude of EPPs (left graph) and the quantal content (right graph), and later application of R-Roscovitine did not increase the amplitude of the response (\*\*\*p \< 0.001, ANOVA).(B) Example of EPPs recorded in control and SMA mutants in control solution, with R-Roscovitine and with ω-Agatoxin IVA plus R-Roscovitine. Terminals treated with ω-Agatoxin IVA show a complete block of the evoked response elicited in the presence of R-Roscovitine as illustrated in EPP amplitude (left graph) and quantal content (right graph), both in control (p\*\*\*\<0.0005, ANOVA) and in SMA mice (p\*\*\*\<0.0005, ANOVA). Numbers inside bars represent the number of muscle fibers and the number of mice, respectively; n.s., no significance.

Discussion {#sec3}
==========

Here, we demonstrated that *in vivo* treatment of SMNΔ7 mice with R-Roscovitine increases survival, beneficially affects formation of Ca~v~2.1 channel clusters at the motor nerve terminal, increases the size of the NMJ, and tends to counteract loss of motoneuron and excitatory somatodendritic inputs on spinal motoneurons. Improved preservation of the neuromuscular system corresponds to increased frequency of spontaneous calcium transients, ameliorated axonal length defects, increased growth cone sizes, and modifications of some of the transcriptome perturbations in Smn-deficient motoneurons. Acute application of R-Roscovitine increases neurotransmitter release in control and SMA motor nerve terminals and favors the recruitment of silenced terminals. Together, these data reveal that R-Roscovitine is a substance that in general supports motoneuron differentiation, function, and maintenance.

R-Roscovitine Treatment Prolongs the Survival of SMA Mice {#sec3.1}
---------------------------------------------------------

R-Roscovitine improves cellular differentiation and maturation of SMA motoneurons *in vitro* and increases neurotransmission at the NMJ in *ex vivo* neuromuscular preparations. Based on our data, the possibility that R-Roscovitine mediates its beneficial effects on the neuromuscular system via direct modulation of the Ca~v~2.1 and Ca~v~2.2 channels are comprehensible and convincing. However, we cannot discard additional mechanisms, especially regarding the improvement of SMA mouse survival. R-Roscovitine binds with high affinity to Cdk-1, 2, 5, 7, and 9 and a few kinases such as CaM kinase 2 (CaMK2A), extracellular signal-regulated kinases 1 and 2 (ERK1/2), and PDXK (pyridoxal kinase) ([@bib10]). Inhibitors of cyclin-dependent kinases impact cell cycle mechanisms and are used for anti-neoplastic therapies ([@bib4]). Furthermore, targeting CaMK2, Erk1, and Erk2 by R-Roscovitine or its analogs might influence motoneuron differentiation/maturation. In addition, inhibition of Cdk-5/p35 by Roscovitine could partially contribute to enhanced activity of the Ca~v~ channels by increasing their interaction with some SNARE proteins ([@bib59]). Finally, it should be mentioned that COOH-R-Roscovitine, the main metabolite of R-Roscovitine, although has less Cdk and kinase inhibition activity ([@bib42]), may have adverse or beneficial side effects that need to be illustrated separately in future long-term approaches on SMA animal models. In principle, the complete survival phenotype is not necessarily explained by the herein studied cellular/molecular mechanisms of R-Roscovitine action, and additional work would be needed to understand this phenotype.

Long-term Exposition to R-Roscovitine Improves Differentiation of Primary Cultured Smn-Deficient Motoneurons {#sec3.2}
------------------------------------------------------------------------------------------------------------

Our systematic R- and S-Roscovitine concentration gradient study on the survival of motoneurons ([Figure S3](#mmc1){ref-type="supplementary-material"}A) discovered that the optimal dose for *in vitro* chronic treatment with R-Roscovitine is 0.5 μM, which is not toxic but still compensates morphological and functional abnormalities. The parameters used to assess cellular differentiation were growth cone sizes ([Figures 4](#fig4){ref-type="fig"}A--4D) and axon lengths ([Figures 4](#fig4){ref-type="fig"}F--4H) on one side, and calcium channel density at SMA growth cones ([Figure 4](#fig4){ref-type="fig"}E) on the other. The observed improvements correlate with the marked enhanced spontaneous Ca^2+^ influx in embryonic SMA motoneurons (*Smn*^*−/−*^*;SMN2*) chronically treated with R-Roscovitine ([Figure 3](#fig3){ref-type="fig"}B). We found no effects on wild-type motoneurons, probably because their cellular differentiation already proceeded correctly and thus is not further improvable by calcium increment. Upon S-Roscovitine treatment (0.5 μM), which inhibits Cdk-1, Cdk-2, and Cdk-5 enzymatic activity with a similar IC~50~ as R-Roscovitine, we observed a slight but not significant increase of spontaneous Ca^2+^ transients after long-term application ([Figure 3](#fig3){ref-type="fig"}B) without compensation of morphological and functional abnormalities in Smn-deficient motoneurons ([Figure 4](#fig4){ref-type="fig"}G). These results, together with the lack of effect of S-Roscovitine on mouse survival ([Figure 1](#fig1){ref-type="fig"}) and neurotransmitter release ([Figure 6](#fig6){ref-type="fig"}) imply that the inhibition of cyclin-dependent kinases by Roscovitine, or by its metabolites, is not enough to improve the SMA phenotype and argues for the importance of R-Roscovitine on Ca^2+^ influx, probably by its direct action on calcium channels. This idea is further supported by two of our observations. First, we discovered, that GV-58, another Ca~v~2.1 and Ca~v~2.2 agonist with a 20-fold lower Cdk-1, Cdk-2, and Cdk-5 activity than R-Roscovitine ([@bib56]), leads to a significantly reduced axon elongation in Smn-deficient motoneurons on laminin-221/211, comparable to R-Roscovitine ([Figure 4](#fig4){ref-type="fig"}H). Second, Cdk-5 depletion in primary cultured motoneurons does not impact spontaneous Ca^2+^ influx in long-term studies ([Figure S2](#mmc1){ref-type="supplementary-material"}C), arguing for an R-Roscovitine mechanism being primarily focused on cellular excitability mediated through Ca~v~2.1 as well as Ca~v~2.2. However, Roscovitine has been shown to affect other ion conductances; for example, it can inhibit L-type VGCCs and several types of potassium channels ([@bib7], [@bib65]). Indeed, some L-type antagonists, such as nifedipine, increase neurotransmitter release at the NMJ ([@bib1], [@bib47], [@bib55]). Nevertheless, the fact that both R- and S-Roscovitine increase the inactivation of L-type channels ([@bib65]) makes less likely the hypothesis that the effects on EPP amplitude and QC in our system correspond to its effect on L-type VGCCs given the lack of positive modulation by S-Roscovitine in our experiments. On the other side, potassium channel blockers enhance secretion by broadening the action potential, which results in a larger Ca^2+^ influx ([@bib8]). Interestingly, 4-aminopyridine, an efficient K~v~ channel blocker, can directly target presynaptic voltage-gated Ca^2+^ channels independent of its effect on K~v~ channels ([@bib63]), which would lead to the potentiation of neurotransmitter release by a double mechanism. All these possibilities need to be verified in the future by additional work.

R-Roscovitine Does Not Affect Ca~v~2.2/2.1 Gene Expression in Smn-Deficient Motoneurons {#sec3.3}
---------------------------------------------------------------------------------------

Smn deficiency affects transcript levels in various cellular systems and *in vivo* ([@bib9], [@bib13], [@bib14], [@bib17], [@bib28], [@bib31], [@bib32], [@bib45], [@bib50], [@bib53], [@bib62], [@bib66]). Thus, to investigate the eventuality that R-Roscovitine somehow alters cellular transcription levels of VGCCs, an RNA-Seq approach was performed ([Figure 5](#fig5){ref-type="fig"}). Interestingly, 305 transcripts with functions in neuronal differentiation and neurotransmission are downregulated by Smn deficiency and upregulated by R-Roscovitine in Smn-deficient motoneurons, not including those of N-type or P/Q-type calcium channels ([Tables S5](#mmc2){ref-type="supplementary-material"} and [S6](#mmc2){ref-type="supplementary-material"}).

The auxiliary subunit α2δ2 (Cacna2d2) of Ca~v~2 channels is one candidate ([Table S5](#mmc2){ref-type="supplementary-material"} and categorized in the "plasma membrane" [Table S6](#mmc2){ref-type="supplementary-material"}), which might support proper Ca~v~2.2/2.1 cluster formations. Cacna2d2 is one of four subunits α2δ1-4 (Cacna2d1-4) that are loosely associated with VGCC complexes and modulate their trafficking ([@bib11], [@bib15]). There is growing evidence that these auxiliary subunits may also have roles in the nervous system not directly linked to calcium channel function. In *D. melanogaster* embryos, the α2δ3 subunit plays a role in synaptogenesis independent of its association with calcium channels ([@bib25]). Other studies describe α2δ2 as a developmental switch that regulates axon growth and regeneration, as α2δ2 gene deletion or silencing promotes axon growth *in vitro* ([@bib57]). *In vivo*, pharmacological blockade of α2δ2 through pregabalin administration enhances axon regeneration in adult mice after spinal cord injury ([@bib57]). Therefore, it remains an open issue whether altered gene expression of these auxiliary VGCC subunits modifies Ca~v~2.1/2.2 cluster formations and in turn affects neurotransmission in SMA mice. SV2A and SV2C ([Table S5](#mmc2){ref-type="supplementary-material"}) are two other candidates related to the regulation of the synaptic vesicles\' readily releasable pool size and the SNARE complex assembly. [@bib58] could already show that the signal intensity of all three SV2 paralogs (A, B, and C) is significantly reduced in motor nerve terminals of skeletal muscles of SMA mice. Apart from Smn deficiency, impaired BDNF/trkB signaling causes a calcium-related phenotype in growth cones ([@bib12]) similar to that observed in SMA motoneurons ([@bib19]), which opens the view on more complex pathways probably affected by Smn deficiency leading to dysregulated motoneuron differentiation. Based on these data, we conclude that long-term application of R-Roscovitine might have effects on gene expression affected by Smn deficiency. For a final conclusion that cellular targets up- or downregulated by R-Roscovitine have an impact on the SMA phenotype, additional experiments with relevant knockout or transgenic animal models are required.

Acute Application of R-Roscovitine Improves Synaptic Transmission at the NMJ {#sec3.4}
----------------------------------------------------------------------------

In our *in vitro* assays, acute application of 5 μM R-Roscovitine increased Ca^2+^ transients frequency ([Figure 3](#fig3){ref-type="fig"}), a concentration in line with experiments on cultured hippocampal neurons ([@bib59]). However, postnatal motor nerve terminals required 100 μM R-Roscovitine to increase neurotransmitter release ([Figures 6](#fig6){ref-type="fig"}, [7](#fig7){ref-type="fig"}, and [8](#fig8){ref-type="fig"}), in line with experiments in frog NMJs ([@bib8]). The difference in the effective concentrations among preparations could be partially explained by their respective state of development---EC~50~ for Ca~v~2.2 channels, predominant in cultured motoneurons, is about 4-fold lower than for Ca~v~2.1 channels, the most abundant at the NMJ ([@bib7], [@bib56])---and by the complexity of the postnatal motor nerve terminal architecture, although additional factors cannot be ruled out.

At postnatal stages, when SMNΔ7 mice are highly affected, synaptic transmission is positively modulated by R-Roscovitine. This effect seems to be presynaptic as there was a reduction of facilitation ([Figures 7](#fig7){ref-type="fig"}A and 7B), indicative of an increase in vesicle release probability. Previous works also demonstrated that R-Roscovitine increases neurotransmitter release at the NMJ ([@bib8]) and central synapses ([@bib22], [@bib23], [@bib39], [@bib59], [@bib64]). This effect has been shown to be mediated by modulation of VGCCs as R-Roscovitine slows the deactivation kinetics of N- and P/Q-type calcium channels ([@bib6], [@bib5], [@bib7], [@bib64]). The agonistic effect of R-Roscovitine is Cdk independent because intracellularly applied R-Roscovitine failed to affect Ca~v~2.2 channels (i.e., to slow deactivation), in contraposition to its extracellular application ([@bib5]). At mouse motor nerve terminals, P/Q-type (Ca~v~2.1) channels are the main channel involved in exocytosis ([@bib21], [@bib47], [@bib52], [@bib58]). By using a specific toxin, we were able to show that R-Roscovitine effects require the activation of P/Q-type calcium channels as ω-Agatoxin IVA totally abolished neurotransmission. R-Roscovitine may directly interact on the calcium channel ([@bib64], [@bib8], [@bib56]) or through the inhibition of Cdk-5. The activation of Cdk-5 phosphorylates Ca~v~2.1 channels, which decreases its interaction with SNARE proteins and depresses neurotransmission ([@bib59]). However, we found that S-Roscovitine decreased secretion and olomoucine had no effect at all, suggesting that the second mechanism is less efficient in our conditions. We found that R-Roscovitine was also able to wake up motor nerve terminals, which are silenced under control conditions ([Figure 7](#fig7){ref-type="fig"}D). At the age our recordings were made (P 9--11), muscle fibers were in the process of changing from multi-to mono-innervation ([@bib40], [@bib49]). It is not well known, however, how this process is regulated. One possibility we favor is by shutting down the calcium channels implicated in neurotransmitter release ([@bib38]). The fast agonistic effect via reduced Ca~v~2.1 channel closing time favors R-Roscovitine as a drug able to support neurotransmission rapidly in SMA.

In summary, our results show that R-Roscovitine in SMA regulates/modulates calcium influx, motoneuron differentiation, enhances neurotransmitter release, and impacts gene expression. Although the data indicate that R-Roscovitine may exert many of the observed *in vitro* and *ex vivo* effects by modulating Ca~v~2.1 and Ca~v~2.2 channels, we cannot exclude the participation of other targets as well, and thus additional experiments such as genetic manipulation of the calcium channels are needed. Moreover, the observed benefit on survival is not necessarily explained by the described calcium enhancement and will require additional work directed to identify other potential mechanisms. Everything considered, R-Roscovitine might support the current SMA therapies with antisense oligonucleotides ([@bib43]) or *SMN* gene transfer via an adeno-associated virus ([@bib67]), in particular at disease onset, over a defined period, to support neurotransmission in a fast manner before SMN upregulation gives rise to its beneficial effects. Beyond this, R-Roscovitine could be useful in all motoneuron diseases with defects in Ca^2+^ homeostasis.

Limitations of the Study {#sec3.5}
------------------------

The beneficial effects of R-Roscovitine on the survival of SMA mice is not entirely explained by its cellular/molecular mechanisms, and further work is needed to understand this phenotype. Especially in the case of the voltage-gated calcium channels, knockout or knockdown approaches will narrow down the specific effects of R-Roscovitine on Ca~v~2.2 and Ca~v~2.1. Also, the transcriptome-affecting effects of R-Roscovitine should be taken into account in further therapeutic applications.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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